AWT038 / Anwita Biosci - LARVOL DELTA

AWT038: Dual GDF15-IL-6 neutralization for cancer cachexia (AACR 2026) - "GDF15 engages GFRAL in the hindbrain to suppress appetite and drive weight loss, and clinical GDF15 blockade (e.g., ponsegromab) has increased body weight, appetite, activity, and lean mass in randomized trials. This dual blockade supports development as supportive care for patients with advanced cancers and elevated GDF15 and/or IL-6, including those receiving platinum-based chemotherapy where GDF15 rises and weight loss is common. If confirmed in clinical studies, AWT038 could complement or surpass single-axis therapies (e.g., GDF15-only inhibitors) by restoring appetite, attenuating inflammation and fatigue, and preserving muscle mass in a population with major unmet need."

Oncology • GDF15 • IL6 • IL6R